Concepedia

Author

Debbie Robbrecht

Erasmus MC Cancer InstituteORCID

Also Known As

D Robbrecht, D. G. J. Robbrecht, D. Robbrecht, D.G. Robbrecht, D.G.J. Robbrecht, Debbie G J Robbrecht, Debbie G. J. Robbrecht, Debbie G. Robbrecht, Debbie G.J. Robbrecht, Debbie GJ Robbrecht

160

Publications

682

Citations

14

H-Index

48

Concepts

All Affiliations

Erasmus MC Cancer InstituteThe Netherlands Cancer InstituteErasmus MCVall d'Hebron Hospital UniversitariOncode Institute
DR

About

Debbie Robbrecht is an author at Erasmus MC Cancer Institute specializing in medicine, oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

322

2

Engineering

1

1

15

3

Health Sciences

1

1

58

4

Public Health

1

1

44

5

Cardiothoracic Surgery

1

1

44

Debbie Robbrecht

×

21

Publications

509

Citations

14

H-Index

YearCitations

Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.

Irene Braña, Geoffrey I. Shapiro, Melissa L. Johnson,

Journal of Clinical Oncology

2021

67

Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

Alwin Krämer, Tilmann Bochtler, Chantal Pauli,

The Lancet

2024

58

Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial

Reetta Virtakoivu, Jenna H. Rannikko, Miro Viitala,

Clinical Cancer Research

2021

51

Association of anti-heart antibodies and circulating immune complexes in the post-pericardiotomy syndrome.

Ivan De Scheerder, Denis Wulfrank, L. Van Renterghem,

PubMed

1984

44

Safety, PK/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP).

Morten Mau‐Sørensen, Willeke Ros, María E. Rodríguez-Ruiz,

Journal of Clinical Oncology

2018

40

Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial

Jenna H. Rannikko, Loïc Verlingue, Maria J. de Miguel,

Cell Reports Medicine

2023

25

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

Debbie Robbrecht, Christiane Jungels, Morten Mau‐Sørensen,

British Journal of Cancer

2021

24

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

Neeltje Steeghs, Carlos Gomez‐Roca, Kristoffer Staal Rohrberg,

Clinical Cancer Research

2024

22

Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)

Ignacio Melero, Eduardo Castañón Álvarez, Morten Mau‐Sørensen,

Annals of Oncology

2018

19

Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer

Pauline A.J. Mendelaar, Debbie Robbrecht, Maud Rijnders,

Molecular Oncology

2022

18

Page 1